The arylamine N-acetyltransferase (NAT) enzymes are xenobiotic metabolizing enzymes that have been found in a large range of eukaryotes and prokaryotes. These enzymes catalyse the acetylation of arylamine drugs and/or pollutants. Recently, a Bacillus anthracis NAT isoform (BanatC) has been cloned and shown to acetylate the sulfonamide antimicrobial sulfamethoxazole (SMX). Subsequently, it was shown that BanatC contributes to the resistance of this bacterium to SMX. Here, the crystallization and the X-ray characterization of BanatC (Y38F mutant) are reported. The crystals belong to the tetragonal space group P4 1 2 1 2 or P4 3 2 1 2, with unit-cell parameters a = b = 53.70, c = 172.40 Å , and diffract to 1.95 Å resolution on a synchrotron source.
Introduction
Arylamine N-acetyltransferases (NATs) are phase II xenobiotic metabolizing enzymes that catalyse the acetyl-CoA-dependent Nand O-acetylation of several arylamines, hydrazines and their N-hydroxylated metabolites (Riddle & Jencks, 1971) . NATs play an important role in the detoxication and/or bioactivation of numerous drugs and xenobiotics (Hein et al., 2000; . Initially identified in humans and other vertebrates (mouse, rabbit), NAT enzymes have now been identified in a range of prokaryotic species (Sim et al., 2007) . To date, the X-ray structures of four bacterial NATs have been published (Sinclair et al., 2000; Sandy et al., 2002; Holton et al., 2005; Westwood et al., 2005) . Recently, the human NAT1 and NAT2 isoform structures were released in the Protein Data Bank. All structures indicate that NAT enzymes possess a conserved three-domain fold whose active sites contain a triad of residues (cysteine-histidine-aspartate) that catalyse substrate acetylation (Sim et al., 2007) .
Bacillus anthracis is a Gram-positive bacterium that causes anthrax in animals and humans (Mock & Fouet, 2001) . We have recently shown that this bacterium possess three NAT homologues (BanatA, BanatB and BanatC; Pluvinage et al., 2007) . Interestingly, BanatC was found to efficiently acetylate the sulfonamide antimicrobial SMX and to afford higher than normal resistance to sulfamethoxazole (SMX) in recombinant Escherichia coli cells .
Because this enzyme could contribute to the resistance of B. anthracis to SMX, we focused on structural studies of this NAT isoform. Whereas wild-type BanatC proved difficult to crystallize, a BanatC mutant (in which the Tyr38 residue was engineered to a Phe residue) displaying the same enzymatic characteristics as wild-type BanatC was found to crystallize and to diffract to 1.95 Å . Here, we describe the preliminary X-ray study of this NAT enzyme isolated from B. anthracis.
Materials and methods

Cloning, expression and purification
The BanatC open reading frame was cloned into the pET28a vector (Novagen) and expressed in E. coli strain BL21 (DE3). Details of cloning and expression have been published elsewhere . The Y38F mutant of BanatC was created by PCR using the mutagenesis primer 5 0 -ATTCTCCCCTTCGAAAATCTT-3 0 and reverse primer 5 0 -AAGATTTTCGAAGGGGAGAAT-3 0 . Recombinant BanatC and Y38F BanatC were purified using HIS-select nickel resin (Sigma) as described in Pluvinage et al. (2007) . The protein products contain an N-terminal hexahistidine tag followed by a linker (sequence SSGLVPRGSHMASMTGGQQMGRGS) which is fused directly to Met1 of the BanatC sequence.
Purity of protein samples (in 25 mM Tris-HCl pH 7.5, 1 mM EDTA) was assessed by SDS-PAGE and Western blotting as described in Pluvinage et al. (2007) . NAT activity assays were also carried out as described in Pluvinage et al. (2007) . Recombinant proteins were then concentrated to 8 mg ml À1 using Amicon ultracentrifugation concentrators (10 kDa molecular-weight cutoff, Millipore).
Crystallization
Crystallization trials were performed at 294 K with the AmSO4 Suite (Qiagen) and CrystalQuick microplates (Greiner) using the hanging-drop vapour-diffusion method by mixing 1.3 ml concentrated protein solution with 0.7 ml reservoir solution. Microcrystals were observed after two weeks with several solutions (Nos. 23, 31, 37, 45) . Using a mixture of 2 ml protein solution and 1 ml reservoir solution, the crystallization conditions were optimized on EasyXtal Tools X-Seal (Qiagen) with 1.8 M ammonium sulfate and 0.17 M potassium nitrate. Crystals suitable for X-ray analysis grow in 5-7 d to maximal dimensions of 120 Â 120 Â 50 mm. For cryoprotection, the crystal was fished from the drop, dunked directly in sodium formate (7 M), mounted in a cryoloop (Hampton Research) and immersed in liquid nitrogen prior to X-ray diffraction analysis.
Data collection
Diffraction data were collected at 100 K on beamline ID23-1 at the ESRF using a MAR CCD detector. The parameters used were an exposure time of 0.1 s with a transmission of 16%. 130 images were collected with 1 oscillation per image at a wavelength of 1.07225 Å . The data set was then processed using XDS (Kabsch, 1993) .
Results and discussion
BanatC has been reported to be a NAT enzyme that contributes to the resistance of B. anthracis to the sulfonamide antibiotic SMX . This NAT isoform could therefore be a possible drug target, as has been suggested for other bacterial NAT enzymes such as the Mycobacterium tuberculosis isoform (Upton et al., 2001) . However, so far crystallization trials of the BanatC isoform have been unsuccessful. The presence in large-scale preparations of a proteolytic fragment (30 kDa) of the BanatC enzyme could explain, at least in part, the difficulties in obtaining crystals. Although several different culture conditions were tested for the production of BanatC, significant quantities of the 30 kDa fragment were found in the purified fractions. Therefore, we tested whether single-point mutants of the BanatC enzyme could be used for crystallization trials. We took advantage of a mutation study carried out in our laboratory aimed at characterizing the importance of the catalytic residues in bacterial NAT enzymes (Atmane et al., 2007) . One BanatC mutant (Y38F) was found to display identical enzymatic properties (data not shown) to those of the wild-type enzyme and based on this was used as a candidate for crystallization trials. As shown in Fig. 1 , SDS-PAGE ( Fig. 1a) and Western blot (Fig. 1b) analysis of purified BanatC and the Y38F mutant indicated that both proteins display a molecular weight of 34 kDa that is consistent with predicted values. Moreover, the proteolytic fragment of 30 kDa was found in the purified samples of wild-type and Y38F BanatC. However, both amido-black staining and Western-blot analysis showed that much less proteolysis occurred with Y38F BanatC compared with the wild-type enzyme. In contrast to BanatC, most eukaryotic and prokaryotic NAT enzymes have a Phe residue instead of a Tyr residue at this highly conserved position (Westwood et al., 2005) . So far, we have no clear explanation as to why replacement of the Tyr residue of BanatC by a Phe residue leads to decreased proteolysis when recombinantly expressed in E. coli. As shown in Fig. 2 , crystals suitable for X-ray analysis were observed within one week using optimized conditions (1.8 M ammonium sulfate and 0.17 M potassium nitrate). Crystals grew to maximum dimensions of 120 Â 120 Â 50 mm. A complete X-ray diffraction data set was collected to 1.95 Å resolution. Datacollection statistics are presented in Table 1 . The crystals had tetragonal symmetry, with unit-cell parameters a = 53.70, b = 53.70, c = 172.40 Å , and belonged to space group P4 1 2 1 2 or P4 3 2 1 2. Molecular replacement using the structures of other bacterial NAT enzymes (Sinclair et al., 2000; Sandy et al., 2002; Holton et al., 2005; Westwood et al., 2005) will be used to attempt to solve the structure of the BanatC isoform.
